Stockscreener 앱 받기
0.6736
0.48%
0.0032
시간 외 거래:
.67
-0.0036
-0.53%
전일 마감가:
$0.6704
열려 있는:
$0.6705
하루 거래량:
26,943
Relative Volume:
0.31
시가총액:
$17.72M
수익:
-
순이익/손실:
$-60.11M
주가수익비율:
-0.155
EPS:
-4.347
순현금흐름:
$-12.04M
1주 성능:
-5.14%
1개월 성능:
-6.65%
6개월 성능:
-30.56%
1년 성능:
-11.92%
1일 변동 폭
$0.6612
$0.6785
1주일 범위
$0.6612
$0.7476
52주 변동 폭
$0.6252
$1.45
AEON Biopharma Inc. Stock (AEON) Company Profile
명칭
AEON Biopharma Inc.
전화
(949) 354-6499
주소
5 Park Plaza, Suite 1750, Irvine
Compare AEON vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.6736 | 17.49M | 0 | -60.11M | -12.04M | -4.347 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-18 | 개시 | H.C. Wainwright | Buy |
AEON Biopharma Inc. 주식(AEON)의 최신 뉴스
AEON Biopharma (AEON) Holds Steady at $0.71 as Stock Consolidates Between Key Support and ResistanceSeasonality Effect - newsline.com
AEON Q4 2025 Earnings: Significant EPS Miss as Pre-Revenue Biotech Faces ChallengesRetail Earnings Report - newsline.com
Number of shareholders of AEON Biopharma, Inc. – AMEX:AEON - TradingView
AEON BIOPHARMA INC (AEON) Stock Chart - ChartMill
AEON Biopharma Presents New Data Supporting Biosimilarity of ABP-450 to BOTOX at AHS 2026 Annual Meeting - Moomoo
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society - The Manila Times
Botox biosimilar ABP-450 shows similar structure and activity - Stock Titan
AEON Biopharma Presents New Data Supporting Biosimilarity of ABP-450 to BOTOX® at AHS 2026 Annual Meeting - Quiver Quantitative
AEON Technical Analysis | Trend, Signals & Chart Patterns | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma (AEON) Surges 5.6% as Bulls Test Key Resistance at $0.80Factor ETF Flow - newsline.com
AEON Biopharma Edges Higher: Stock Rises 2.75% as it Tests Key ResistanceHigh Conviction Picks - The Legal Advocate
AEON Q4 2025 Earnings: Deep EPS Miss Amid Pre-Revenue StageEPS Miss Report - The Legal Advocate
AEON Biopharma Q4 2025 Earnings: Major EPS Miss and No Revenue Weigh on Investor SentimentEarnings Expansion Phase - Newser
AEON Biopharma Inc. (AEON) Q4 2025 Earnings: Significant EPS Miss and Stock Decline Amid Development ChallengesHigh Growth Earnings - Newser
AEON Biopharma Dips 2.74% as Stock Nears Critical Support at $0.76Watchlist Stock Ideas - Newser
AEON Q4 2025 Earnings: Wider-Than-Expected Loss as Biotech Continues Pre-Revenue PhaseAnalyst Earnings Estimate - newsline.com
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
AEON Stock Price, Quote & Chart | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON SEC FilingsAeon Biopharma 10-K, 10-Q, 8-K Forms - Stock Titan
AEON Biopharma shares fall over 2% on quarterly loss - Investing.com
AEON Biopharma shares fall over 2% on quarterly loss By Investing.com - Investing.com South Africa
AEON Biopharma Reports Q1 Financial Results - Intellectia AI
AEON Biopharma Releases Updated Investor Relations Presentation - TipRanks
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma (AEON) releases May 2026 corporate investor presentation via Form 8-K - Stock Titan
AEON Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
AEON Biopharma (NYSE: AEON) Q1 2026 loss, financing deals and going concern risk - Stock Titan
AEON Biopharma (NYSE: AEON) Q1 2026 loss, FDA boosts ABP-450 plan and debt cut - Stock Titan
AEON’s Botox biosimilar plan gets FDA feedback as debt falls 90% - Stock Titan
TradingKey - TradingKey
AEON Biopharma (AEON) details 2026 meeting, director elections and KPMG ratification - Stock Titan
AEON Biopharma Sets Annual Shareholder Meeting - The Manila Times
AEON cites going concern audit note, cash into Q3 2026 - Stock Titan
AEON Biopharma receives additional NYSE American non-compliance notice - MSN
AEON Bio (AEON) Stock: Why Brand Strength (Eye on Rally) 2026-04-20Market Movers - Cổng thông tin điện tử tỉnh Tây Ninh
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Eli Lilly and Company, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
AEON (AEON Biopharma) PB Ratio : (As of Apr. 10, 2026) - GuruFocus
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Weekly Earnings: Will AEON Biopharma Inc be affected by tariffs2026 Big Picture & High Conviction Investment Ideas - baoquankhu1.vn
What is the bull case for AEON Bio (AEON) Stock | AEON Q4 2025 Earnings: AEON Biopharma Inc. misses EPS, no revenue postedAnnual Earnings Summary - newsline.com
Is AEON Bio (AEON) Stock Rebounding | Price at $0.90, Up 1.27%Rip Sell Trade - The Legal Advocate
AEON Biopharma Receives NYSE American Non-Compliance Notice Due to Stockholders’ Equity Deficit and Ongoing Listing Challenges - Minichart
AEON Biopharma Receives Additional NYSE American Noncompliance Notice - The Globe and Mail
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards - The Manila Times
AEON Biopharma, Inc. (AEON) stock price, news, quote and history - Yahoo Finance Singapore
AEON Biopharma Receives Second NYSE American Notice for Listing Non-Compliance - geneonline.com
AEON (AEON) CFO awarded 754,717 restricted stock units vesting over four years - Stock Titan
AEON Biopharma (AEON) CFO John Bencich files initial insider ownership report - Stock Titan
AEON Biopharma Faces Listing Compliance Risk - Intellectia AI
AEON Biopharma Inc. (AEON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):